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Hypertrichosis is defined as the excessive growth and
thickness of hair in the normal distribution of hair and
should be distinguished from hirsutism or excessive hair
growth in females distributed in the male pattern [1]. It
may be congenital, acquired, localized, or diffuse andoi.org/10.1016/j.ijpam.2015.05.0
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pigmentation. Acquired hypertrichosis has been associated
with conditions such as atopic dermatitis and vernal kera-
toconjunctivitis, HIV, porphyria, hypothyroidism, anorexia
nervosa, paraneoplasia, systemic lupus, and trauma [1e3].
Hemophagocytic lymphohistiocytosis is a rare group of
disorders manifesting as immune disregulation. Familial,
autosomal recessive and acquired forms are diagnosed by
fulfilling specific criteria and can be triggered by infections,
malignancies, and autoimmune diseases [4]. Characteristic01.
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Figure 2 CSA-induced hypertrichosis of upper lip and face
manifesting as a moustache, sideburns and downy facial hairs.
e2 J. El Mansoury, J.N. Mbekeaniimpaired natural killer and cytotoxic T cell function results
in excessive cytokines that lead to the accumulation of T
cell lymphocytes and histiocytes (macrophages) in multiple
organs including lymph nodes, the liver, and spleen [4]. To
date, HLH has not been associated with hypertrichosis or
hursutism. In addition to a significant temporal relation
with hospitalization and chemotherapy, it seems the likely
cause of hypertrichosis in our patient is acquired and
iatrogenic.
Drugs associated with hypertrichosis include, cyclo-
sporine A, minoxidil, phenytoin, steroids, epidermal growth
factor inhibitors, tyrosine kinase inhibitors, interferon A,
tacrolimus, and prostaglandin analogues used for glau-
coma, such as latanoprost and travaprost [1e3,5]. Of the
medications administered for HLH and pre-BMT manage-
ment, the most likely culprit causing hypertrichosis and
eyelash trichomegaly is cyclosporine A with possible
potentiation by simultaneous prednisolone therapy [2,6].
Cyclosporine A, a potent immunosuppressive agent that
specifically downregulates T cell-mediated immunity
through interleukin-2 (IL2) inhibition can be administered
as part of therapeutic regime for various auto-immune
disorders, malignancies and to ameliorate allogeneic graft
rejection. In this patient, it was utilized as part of the HLH-
2004 treatment protocol [7] and in preparation for poten-
tially curative BMT. Known complications of CSA therapy
include nephrotoxicity, hepatotoxicity, various infections,
tremors, gingival hyperplasia and hypertrichosis [6]. The
frequency of CSA hypertrichosis and eyelash trichomegaly
varies with different reports [2,6,8]. Although higher fre-
quencies are noted in pediatric and female patients and at
higher doses of CSA [2,6], this side effect does not occur
universally in all patients, suggesting an element of
idiosyncrasy.
The mechanism for excessive hair growth has not been
conclusively elucidated. Takahashi and Kamimura [9] in
their studies of cultured murine hair epithelial cells found
that CSA at various doses stimulated hair and epidermal
keratinocyte growth, when compared to control cells, and
simultaneously down-regulating certain protein kinase C
isoenzymes. Since protein kinase C, a key enzyme system
influencing cell proliferation and differentiation, has known
negative hair-growing effects, they speculated that this
might be the pathway that leads to CSA hypertrichosis.
Interestingly, the downregulation of protein kinase CFigure 1 CSA-induced hypertrichosis with eyelash trichomegaly a
long, thick and dark.isoenzymes is thought also to be the means by which CSA
inhibits IL2 and thus T cell immunity, thereby causing im-
mune modulation. If indeed CSA exerts potent immuno-
suppression and hypertrichosis effects by a similar
mechanism, the question that begs to be answered is why
there is selective vulnerability to hypertrichosis and
trichomegaly.
Our patient, a vulnerable candidate, exhibited diffuse
hypertrichosis, and eyelash trichomegaly, likely associated
with systemic cyclosporine and steroid administration.
Although occasionally of cosmetic concern, this well-
recognized side effect is rarely of clinical significance and
resolves on termination of therapy. Rarely does iatrogenic
hypertrichosis require intervention and hair trimming,
shaving, plucking, or application of depilating creams can
be used in severe cases. These measures might be consid-
ered, in our patient, in the unlikely event of dystrichiasis
[10], (misdirected accessory eyelashes towards the globe),
or should cyclosporine need to be employed post-BMT, to
ameliorate graft vs host disease, with unacceptable cosm-
esis from excessive hypertrichosis. A case of a patient with
HLH and similar CSA-hypertrichosis after HLH-2004 therapy,
has been described who displayed the expected resolution
upon cessation of therapy [11]. Likewise, we fully expect
complete resolution of hypertrichosis and trichomegalynd unibrow. Head hair, eyelashes and brow hairs are unusually
Cyclosporine A hypertrichosis in a patient e3without intervention and will continue to review this pa-
tient at regular intervals during his clinical course (Figs. 1
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